pharmaceutical investing Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat
pharmaceutical investing FDA Grants Rare Pediatric Disease Designation to A4250; Albireo Eligible to Apply for Priority Review Voucher
Revolve Receives Approval from the Alberta Utilities Commission for the 15.7 MW Bright Meadows Solar Project